MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcf.2026.05.009

Медицинская библиотека · Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026

Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosis.

Singh Akruti, Horvit Andrew, Abramowitz Jessica, Abreu Marconi, Kaput Katie, Neece Amber, Ratti Gregory A, Finklea James D, Jain Raksha, Mirfakhraee Sasan

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

GLP-1 receptor agonists (GLP-1 RAs) are being increasingly prescribed off-label to people with cystic fibrosis (pwCF) for weight management or cystic fibrosis-related diabetes (CFRD). However, the metabolic and pulmonary consequences of GLP-1 RA discontinuation in pwCF are unknown. We evaluated changes in body mass index (BMI), glucose control, pulmonary function, and pulmonary exacerbations following GLP-1 RA withdrawal.

METHODS

We conducted a single-arm, retrospective, multi-center cohort study of adults with CF treated with GLP-1 RAs who subsequently discontinued treatment for ≥ 6 months to assess the effect on metabolic and pulmonary outcomes. BMI, hemoglobin A1c (HbA1c), percent predicted forced expiratory volume in 1 second (FEV1), and forced vital capacity (FVC) were collected prior to GLP-1 RA, during GLP-1 RA therapy, and 6 months post-GLP-1 RA discontinuation.

RESULTS

Fourteen pwCF (four male; median age 45 years) met inclusion criteria. Median BMI at GLP-1 RA initiation was 34.3 kg/m². BMI decreased by a median of 10.8% during GLP-1 RA therapy, followed by a median increase of 5.6% in the six months after GLP-1 RA discontinuation. Median FEV1 increased from 64.5% at baseline to 76.5% on therapy and remained stable at 73.0% six months after GLP-1 RA discontinuation; similar patterns were observed for FVC. Annualized FEV1 slopes were -0.9% pre-treatment, +1.3% during treatment, and +0.9% post discontinuation. HbA1c improved with GLP-1 RA therapy and remained stable after withdrawal. Pulmonary exacerbations remained infrequent in all periods.

CONCLUSIONS

In pwCF, GLP-1 RA discontinuation is followed by partial weight regain but with stable pulmonary and glycemic outcomes. Larger, prospective studies are needed to confirm these preliminary findings and guide clinical decision-making regarding GLP-1 RA use in this population.

Для цитирования: Singh Akruti, Horvit Andrew, Abramowitz Jessica, Abreu Marconi, Kaput Katie, Neece Amber, Ratti Gregory A, Finklea James D, Jain Raksha, Mirfakhraee Sasan. Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosis.. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2026. DOI: 10.1016/j.jcf.2026.05.009.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.